Premium
Mutation status and surgical selection
Author(s) -
Margonis Georgios A,
Kreis Martin E,
Wolfgang Christopher L,
Weiss Matthew J
Publication year - 2019
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25413
Subject(s) - metastasectomy , kras , medicine , selection (genetic algorithm) , mutation , oncology , overall survival , surgical resection , cancer , metastasis , genetics , gene , colorectal cancer , artificial intelligence , biology , computer science
Current evidence cannot support denying metastasectomy in otherwise resectable patients solely based on their overall KRAS or BRAF mutational status. The combination of KRAS or BRAF mutational status with certain clinicopathologic characteristics has defined groups of patients who may not derive benefit from metastasectomy, but external validation is needed. The effect of certain KRAS or BRAF variants on survival may be more pronounced and therefore future studies should consider them for surgical selection.